Skip to main content

Ravulizumab use while Breastfeeding

Drugs containing Ravulizumab: Ultomiris

Medically reviewed by Drugs.com. Last updated on Mar 12, 2021.

Ravulizumab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of ravulizumab during breastfeeding. Because ravulizumab is a large protein molecule with a molecular weight of about 148,000 Da, absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. The manufacturer recommends that breastfeeding be discontinued during ravulizumab therapy and for 8 months after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Eculizumab

Substance Identification

Substance Name

Ravulizumab

CAS Registry Number

1803171-55-2

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.